Why the PD-L1-high subgroup could be crucial for Summit Therapeutics’ global strategy
Summit shares rise after ivonescimab delivers 30.8-month survival versus 22.6 months for pembrolizumab in China’s HARMONi-2 trial.
Pharma & Biotech
Pharma & Biotech
Lancet Oncology publishes Summit’s global ivonescimab Phase 3 with PFS at 6.8 months versus 4.4
Global HARMONi data show ivonescimab plus chemotherapy reduced progression or death risk by 48% after third-generation EGFR-TKI failure, while overall survival had not reached statistical significance at the primary analysis.
Pharma & Biotech
Akeso adds B7-H3 to its ADC strategy, but AK157D1 enters a field where a rival is already under FDA review
China has cleared Akeso’s AK157D1 for Phase 1 testing in advanced solid tumors, adding a DXd-class B7-H3 programme to a target already attracting late-stage ADC competition.
Pharma & Biotech
Akeso is betting a dual-target ADC can break through breast cancer’s increasingly crowded treatment field
Akeso starts Phase II testing of AK146D1 plus ivonescimab in advanced breast cancer. See what the dual-target ADC strategy must prove.
Pharma & Biotech
What Akeso’s AK138D1 and ivonescimab combination must prove in advanced NSCLC
Akeso has started a Phase Ib/II lung cancer trial of HER3 ADC AK138D1 with ivonescimab. See what the combination must prove.
Pharma & Biotech
Why Akeso’s gumokimab approval could sharpen China’s psoriasis biologics race
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.
Pharma & Biotech
Can Akeso’s ivonescimab ASCO plenary data reset expectations in lung cancer?
Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.
Pharma & Biotech
Akeso’s gumokimab advances to NMPA review in ankylosing spondylitis: Is China’s IL-17 race entering a new phase?
Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after Phase 3 success. Find out what this could mean for IL-17 therapies in China.
Pharma & Biotech
Akeso’s cadonilimab outperforms PD-1 inhibitors in real-world gastric cancer study
Cadonilimab outperforms PD-1 inhibitors in PD-L1-low gastric cancer patients. Find out what this means for global immunotherapy standards.
Pharma & Biotech
Ivonescimab delivers 80% response in TNBC: Is Akeso redefining PD-1 treatment?
Ivonescimab shows 80 percent response in TNBC Phase II study. Explore how Akeso’s bispecific strategy could reshape PD-1 therapy in first-line settings.